UK's MHRA approves beremagene geperpavec for treatment of dystrophic epidermolysis bullosa
Krystal Biotech Inc KRYS
$306.29
▼ -3.16%
($-10.01)
Open
$312.29
Prev Close
$316.30
Day Range
$305.99 – $314.05
52W Range
$122.80 – $319.48
Market Cap
$9.03B
P/E (TTM)
40.13
Beta
0.51
EPS (TTM)
$7.48
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-09-20 |
| Shares Out. | 29,440,000 |
| Website | krystalbio.com/ ↗ |
| Phone | 13026587581 |
Krystal Biotech Inc is a publicly traded company under the ticker symbol KRYS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-05-01)
📰 Latest News for KRYS
MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Krystal Biotech, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation